.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Cerilliant
Chubb
QuintilesIMS
Queensland Health
Colorcon
Farmers Insurance
McKesson
Johnson and Johnson
Dow

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: ➤ Subscribe

« Back to Dashboard

Details for Patent: ➤ Subscribe

Title: Purine derivatives
Abstract:9-Hydroxyethoxymethyl (and related) derivatives of certain 6-, and 2,6-substituted purines have been discovered to have potent anti-viral activities. Novel compounds and their pharmaceutically acceptable salts, pharmaceutical formulations containing the compounds of this invention, and the treatment of viral infections with these formulations are all disclosed. 9-(2-hydroxyethoxymethyl) guanine and 2-amino-9-(2-hydroxyethoxymethyl)adenine are examples of especially active compounds of this invention.
Inventor(s): Schaeffer; Howard J. (Raleigh, NC)
Assignee: Burroughs Wellcome Co. (Research Triangle Park, NC)
Filing Date:Feb 01, 1978
Application Number:05/874,060
Claims:1. 9-(2-propionyloxyethoxymethyl)guanine.

2. A pharmaceutically acceptable salt of 9-(2-propionyloxythoxymethyl)guanine.

3. 9-[2(2,2-Dimethylpropionyloxy)ethoxymethyl]guanine or a pharmaceutically acceptable salt thereof.

4. The method of treating a susceptible viral infection in a mammal having said viral infection which comprises the administration of an effective antiviral nontoxic amount of 9-(2-propionyloxyethoxymethyl)guanine or a pharmaceutically acceptable salt thereof.

5. A pharmaceutical composition comprising an effective antiviral amount of 9-(2-propionyloxyethoxymethyl)guanine or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier therefore.

6. The method of treating a susceptible viral infection in a mammal having said viral infection which comprises the administration of an effective antiviral nontoxic amount of 9-[2-(2-Dimethylpropionyloxyethoxymethyl]guanine or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition comprising an effective antiviral amount of 9-[2-(2,2-Dimethylpropionyloxyethoxymethyl]guanine or a pharmaceutically acceptable salt thereof together with a pharamaceutically acceptable carrier therefore.

8. The method according to claim 4 in which the treated viral infection is caused by a herpes virus.

9. The method according to claim 6 in which the treated viral infection is caused by a herpes virus.

10. 9-(2-acetyloxyethoxymethyl) guanine.

11. A pharmacuetically acceptable salt of 9-(2-acetyloxyethoxymethyl) guanine.

12. A pharmacuetical composition comprising an effective antiviral amount of 9-(2-acetyloxyethoxymethyl) guanine or a pharmacuetically acceptable salt thereof together with a pharmacuetically acceptable carrier therefore.

13. The method of treating a susceptable viral infection in a mammal having said viral infection which comprises the administration of an effective antiviral non toxic amount of 9-(2-acetyloxyethoxymethyl) guanine or a pharmacuetically acceptable salt thereof.

14. The method of claim 13 in which the viral infection is a herpes virus infection.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Healthtrust
Citi
Federal Trade Commission
McKinsey
Boehringer Ingelheim
AstraZeneca
Johnson and Johnson
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot